Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab

Scientific paper - Original scientific paper

• Author: Ivan Adamec
• Author: Dunja Rogić; MBZ: 147641
• Author: Monika-Gabriele Penz
• Author: Carola Braun
• Author: Mario Habek
• Author's institution: University of Zagreb; School of Medicine; (Department of Neurology)
• Scientific / art field, discipline and subdiscipline: BIOMEDICINE AND HEALTHCARE; Clinical Medical Sciences; Neurology

Abstract (english)

Objectives: To report clinical outcome, development of humoral and T-cell mediated immunity in convalescent COVID-19 people with multiple sclerosis (pwMS) treated with ofatumumab in the ALITHIOS study from a single center.
-----
Methods: Testing for SARS-Cov2 IgG antibodies was performed on two occasions with at least three months apart between the two testing. During the second antibody testing, interferon-γ ELISpot was used to assess cellular immunity.
-----
Results: All four subjects had mild COVID-19 infection without any sequelae. In all subjects except subject 2, COVID-19 was confirmed with PCR. Subjects 1, 2 and 4 had normal levels of IgM and IgG without measurable counts of CD19 cells prior to COVID-19. Subject 3 administered the last dose of ofatumumab 24 days prior to COVID-19 symptoms, but had a gap of 28 weeks of ofatumumab application beforehand due to low IgM levels. Subject 4 received COVID-19 vaccinations before second testing, so second testing and T-cell immunity testing were not performed. Subjects who were CD19 depleted did not had measurable levels of SARS-Cov2 IgG antibodies. Subject 3 had first and second SARS-COV2 titer of 118 U/ml and > 250 U/ml, respectively. All three pwMS showed T cell immunity against SARS-CoV-2. Quotient of basal spots divided by interferon-γ secreting spot forming units were 4, 8 and 14.7 SI in subjects 1, 2 and 3, respectively (>3 considered reactive).

• Keywords (english): Adult; Antibodies, Monoclonal, Humanized / therapeutic use*; Antibodies, Viral / blood; COVID-19 / complications; COVID-19 / immunology*; Clinical Trials, Phase III as Topic; Female; Humans; Immunity, Cellular / immunology; Immunity, Humoral / immunology; Male; Multiple Sclerosis / complications*; Multiple Sclerosis / immunology*
• Language: english
• Publication type: Scientific paper - Original scientific paper
• Publication status: Published
• Peer review: Peer review
• Publication version: Published version
• Journal title: Journal of Neuroimmunology
• Numbering: vol. 362, 577788
• p-ISSN: 0165-5728
• e-ISSN: 1872-8421
• DOI: https://doi.org/10.1016/j.jneuroim.2021.577788
• URN:NBN: urn:nbn:hr:105:570068
• Publication: 2022-01-15
• Document URL: https://linkinghub.elsevier.com/retrieve/pii/S0165572821003155
• Type of resource: Text
• Access conditions: Open access
• Created on: 2022-02-03 08:22:46